Page last updated: 2024-11-05

lithium citrate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Lithium citrate is a salt formed by the reaction of lithium hydroxide and citric acid. It is a white, crystalline solid that is soluble in water. It is used as a treatment for bipolar disorder, and is also being investigated for its potential use in the treatment of other conditions, such as Alzheimer's disease and autism spectrum disorder. Lithium citrate is thought to work by affecting the levels of certain neurotransmitters in the brain. It is typically taken orally as a tablet or capsule. The most common side effects of lithium citrate include nausea, vomiting, diarrhea, and tremor. However, more serious side effects can occur, such as kidney problems and thyroid problems. It is important to talk to a doctor before taking lithium citrate, as it can interact with other medications. Lithium citrate is a relatively safe medication when taken as prescribed. However, it is important to be aware of the potential side effects and to talk to a doctor if you have any concerns.'

lithium citrate: RN given refers to the trilithium salt [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

lithium citrate (anhydrous) : A lithium salt that is the anhydrous form of the trilithium salt of citric acid. The tetrahydrate form is used as a source of lithium for the treatment of anxiety disorders, bipolar disorder, and depression. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID13520
CHEMBL ID1201170
CHEBI ID64735
MeSH IDM0192307

Synonyms (52)

Synonym
unii-3655633623
919-16-4
1,2,3-propanetricarboxylic acid, 2-hydroxy-, lithium salt (1:3)
AKOS015839591
citric acid, trilithium salt
einecs 213-045-8
lithium citrate
lithium citrate (anhydrous)
lithium citrate anhydrous
demalit
trilithium citrate
litarex
6680-58-6
NCGC00095267-01
NCGC00095267-02
SPECTRUM1504269
HMS2093G04
citric acid, lithium salt
trilithium 2-hydroxypropane-1,2,3-tricarboxylate
chebi:64735 ,
CHEMBL1201170
HMS1923K13
einecs 233-819-9
nsc-758700
lithium citrate (anh.)
anhydrous lithium citrate
anh. lithium citrate
lithium (as citrate)
citric acid trilithium salt
FT-0636234
AKOS015902460
lithium citrate [mi]
2-hydroxy-1,2,3-propanetricarboxylic acid lithium salt (1:3)
CCG-213298
WJSIUCDMWSDDCE-UHFFFAOYSA-K
lithium citrate tribasic 4-hydrate
1313437-84-1
lithium 2-hydroxypropane-1,2,3-tricarboxylate
citric acid,lithium salt
DTXSID70883185 ,
DB14507
trilithium;2-hydroxypropane-1,2,3-tricarboxylate
Q2351742
demalit; litarex; lithonate s
lithium (citrate)
lithium2-hydroxypropane-1,2,3-tricarboxylate
trilithium(1+) ion 2-hydroxypropane-1,2,3-tricarboxylate
EN300-267798
lithium citrate (mart.)
lithium citrate (ep monograph)
dtxcid401022738
lithium citrate (usp monograph)

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The bioavailability of lithium citrate syrup was compared with that of regular lithium carbonate tablets in 18 healthy male human volunteers."( Bioavailability of lithium from lithium citrate syrup versus conventional lithium carbonate tablets.
Benson, K; De Witte, TC; Guelen, PJ; Janssen, TJ; Vree, TB, 1992
)
0.88
" The results show that whilst the 12-h steady-state levels are similar, there are significant differences in the degree and rate of absorption between the two preparations."( Solid versus liquid lithium--a pharmacokinetic study.
Ascough, G; Markar, HR, 1991
)
0.28

Dosage Studied

Lithium citrate was initiated at a dosage of 45 mg/kg per day after diagnosis. Patients were each divided into two groups: Dosage with immediate-release lithium carbonate or a sustained-release formulation, lithium citrate.

ExcerptRelevanceReference
" Maximum lithium serum concentrations, however, were only about 10 per cent higher after syrup dosing and serum concentrations resulting from syrup and tablets were almost superimposable from 2 h after dosing."( Bioavailability of lithium from lithium citrate syrup versus conventional lithium carbonate tablets.
Benson, K; De Witte, TC; Guelen, PJ; Janssen, TJ; Vree, TB, 1992
)
0.57
" GFR correlated significantly with sclerotic glomeruli as well as atrophic tubules in patients on a multiple dosage schedule, whereas no relationship was seen in patients receiving lithium in a single daily dose."( Long-term effects of lithium on the kidney: functional-morphological correlations.
Bolwig, TG; Brun, C; Hetmar, O; Ladefoged, J; Larsen, S, 1989
)
0.28
"Antipsychotic dosing for acute mania has not been well studied."( Acute mania: haloperidol dose and augmentation with lithium or lorazepam.
Allen, MH; Charles, O; Chou, JC; Czobor, P; Trujillo, M; Tuma, I; Volavka, J; Winsberg, B, 1999
)
0.3
" Therefore, a dose-response test curve was constructed to determine whether small differences in serum Li could be detected in response to ingestion of variable Li doses indicative of full or partial dietary compliance."( Serum lithium concentration can be used to assess dietary compliance in adults.
Bessesen, DH; Donahoo, WT; Grunwald, GK; Higbee, DR; Higgins, JA; Lei, S, 2004
)
0.32
" Intervention group (N = 42) and historical control group (N = 55) patients were each divided into two groups: Dosage with immediate-release lithium carbonate or a sustained-release formulation, lithium citrate."( A computerised sampling strategy for therapeutic drug monitoring of lithium provides precise estimates and significantly reduces dose-finding time.
Andersson, JE; Angelo, HR; Dalhoff, KP; Hoegberg, LC; Holgersson, B; Jürgens, G; Larsen, EB; Zederkof, VW, 2012
)
0.57
" Lithium citrate was initiated at a dosage of 45 mg/kg per day after diagnosis."( Lithium citrate as treatment of Canavan disease.
Andrés, JL; Boquet, EM; Fernández, LL; Solsona, MD,
)
2.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
lithium salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (43)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (16.28)18.7374
1990's10 (23.26)18.2507
2000's8 (18.60)29.6817
2010's13 (30.23)24.3611
2020's5 (11.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.38 (24.57)
Research Supply Index4.04 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index84.59 (26.88)
Search Engine Supply Index3.89 (0.95)

This Compound (33.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (14.29%)5.53%
Reviews1 (2.04%)6.00%
Case Studies6 (12.24%)4.05%
Observational0 (0.00%)0.25%
Other35 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]